This could be a huge achievement in the field of medical technology, as the collaboration of scientists and tech billionaire Sean Parker’s Institute for Cancer Immunotherapy may have been successful in discovering a a way to foretell whether melanoma patients will get cured by the treatments that target the PD-1 (programmed cell death protein) tumor though a basic blood test, said a paper in scientific journal Nature.
The ex Facebook president has invested an enormous $250 million sum out of his massive property of $3 billion to launch this institute, and then invited hundreds of top scientists from various research universities across the United States to come together and combat cancer through cutting-edge immunotherapy.
The Institute has not presented a cure to the ailment, however, this work could be a good answer to the people waiting for something good from Parker’s organization. This is the first first major scientific paper to publish out of Parker’s organization, which shows great promise and scope, for which the institute may get in touch with other researchers and universities to bring forth the cure of this disease.
Scientists from the University of Pennsylvania and Memorial Sloan-Kettering allied for the very first time to work on this project, and concluded that levels of the blood biomarker versus mutational load may forecast if the cancer patient is responsive to the treatment. The explanations of the findings may be a bit too complex for people with shallow knowledge in the area, but one can always switch to the article in Nature to gain a better read on the subject.
Parker is a great name in tech world, who utilizes every possible resource to gain progress on the path that leads towards his dream. This finding is the very first ray of hope from him and his institute for the masses of humanity.
